Compare IDEXX Laboratories, Inc. (IDXX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Xpeng Inc - ADR — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.4× Xpeng Inc - ADR's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 5,030,325). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Xpeng Inc - ADR for 80 Days on average.
| IDXX | XPEV | |
|---|---|---|
Market Cap | $40.43B | $9.16B |
Volume | 692,164 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $28.07 |
52-Week Low | $504.70 | $9.25 |
Typical Hold Time | 46 Days | 80 Days |
Enterprise Value | $41.32B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
XPeng (XPEV) trades at $9.55, down 0.31% with a bearish technical signal. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a net margin of -4.14%. Recent vehicle deliveries of 41,256 in September 2026 and the upcoming G9L SUV launch at the Paris Motor Show highlight expansion efforts. Analyst consensus is bullish with a $17.55 price target, though earnings misses in Q1 and Q2 2026 raise execution concerns.
The stock presents a high-risk, high-reward opportunity. Significant revenue growth and analyst optimism are offset by persistent losses and competitive pressures. Key catalysts include successful global expansion and profitability improvements, while risks involve execution missteps and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
